Geode Capital Management
AKTX

Geode Capital Management’s Akari Therapeutics AKTX Stock Holding History

Geode Capital Management’s Portfolio AKTX Stock Details AKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-38
Closed -$5.14K – 4762
2023
Q2 		$5.14K Hold
38
– – ﹤0.01% 4740
2023
Q1 		$5.5K Hold
38
– – ﹤0.01% 4789
2022
Q4 		$14K Hold
38
– – ﹤0.01% 4807
2022
Q3 		$19K Hold
38
– – ﹤0.01% 4922
2022
Q2 		$30K Hold
38
– – ﹤0.01% 4868
2022
Q1 		$36K Hold
38
– – ﹤0.01% 4869
2021
Q4 		$45K Hold
38
– – ﹤0.01% 4876
2021
Q3 		$49K Hold
38
– – ﹤0.01% 4782
2021
Q2 		$52K Hold
38
– – ﹤0.01% 4651
2021
Q1 		$79K Buy
+38
New +$86.1K ﹤0.01% 4339

Other funds holding AKTX

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
OFW
Omnia Family Wealth Aventura, Florida $373M AUM 25.3% 1-Year Est. Return
Cerity Partners
Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
TC
Truvestments Capital Sarasota, Florida $554M AUM 32.49% 1-Year Est. Return
CPG
Cornerstone Planning Group Fairfield, New Jersey $749M AUM 17.97% 1-Year Est. Return

Geode Capital Management's AKTX Position: Q3 2023 in Review

Geode Capital Management sold out of Akari Therapeutics (AKTX) in Q3 2023, closing a stake of 38 shares — an estimated $5.14K sold.

Geode Capital Management first reported a position in AKTX in Q1 2021 and held it in 10 quarters. The position peaked at $79K in Q1 2021. 7 funds tracked by Wall St. Rank hold AKTX as of Q3 2023.

  • Geode Capital Management reported no remaining Akari Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Geode Capital Management sold 38 Akari Therapeutics shares in Q3 2023, an estimated $5.14K.
  • Geode Capital Management first reported a position in Akari Therapeutics in Q1 2021 and held it in 10 quarters.
  • Geode Capital Management's Akari Therapeutics position peaked at $79K in Q1 2021.
  • 7 funds tracked by Wall St. Rank held Akari Therapeutics as of Q3 2023.

Based on Geode Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.